Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RaySearch Laboratories AB ( ($SE:RAY.B) ) just unveiled an update.
RaySearch Laboratories AB has secured an additional order for its RayStation software to enhance proton therapy at Stanford Health Care. This order will support advanced proton arc therapy, including upright treatments, and integrate with the Mevion FIT system. This collaboration with Stanford Health Care, Mevion, and Leo Cancer Care exemplifies the integration of hardware, software, and clinical expertise to advance cancer treatment.
The most recent analyst rating on ($SE:RAY.B) stock is a Hold with a SEK241.00 price target. To see the full list of analyst forecasts on RaySearch Laboratories AB stock, see the SE:RAY.B Stock Forecast page.
More about RaySearch Laboratories AB
RaySearch Laboratories AB is a medical technology company specializing in innovative software solutions for cancer treatment. The company markets the RayStation treatment planning system and RayCare oncology information system, along with RayIntelligence and RayCommand. RaySearch’s software is used in over 1,100 clinics across 47 countries, and the company has been listed on Nasdaq Stockholm since 2003.
Average Trading Volume: 127,996
Technical Sentiment Signal: Buy
Current Market Cap: SEK7.78B
For an in-depth examination of RAY.B stock, go to TipRanks’ Overview page.